2024-05-07 21:14:02 ET
Pacira BioSciences, Inc. (PCRX)
Q1 2024 Earnings Conference Call
May 07, 2024, 04:30 PM ET
Company Participants
Susan Mesco - Head of Investor Relations
Frank Lee - Chief Executive Officer
Charles Reinhart - Chief Financial Officer
Jonathan Slonin - Chief Medical Officer
Christian Pedetti - Senior Manager, Investor Relations
Conference Call Participants
Gregory Renza - RBC Capital Markets
David Amsellem - Piper Sandler
Gary Nachman - Raymond James
Balaji Prasad - Barclays
Presentation
Operator
Thank you for standing by. My name is Hermione and I will be your conference operator today. At this time, I would like to welcome everyone to Q1 2024 Pacira BioScience Earnings Conference Call.
All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question-and-answer session. po [Operator instructions] I would now like to turn the call over to Susan Mesco, Head of Investor Relations. Please go ahead.
Susan Mesco
Thank you and good afternoon, everyone. Welcome to today's conference call to discuss our first quarter 2024 financial results. Joining me are Frank Lee, Chief Executive Officer, and Charles Reinhart, Chief Financial Officer. Jonathan Slonin, Chief Medical Officer is also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or the Pacira website.
With that, I will now turn the call over to Frank Lee.
Frank Lee
Thank you, Susan, and good afternoon, everyone. It's been an exciting and productive time since I joined the company earlier this year, and I'm pleased to say sales are off to a solid start and on track, for all three of our trusted opioid-sparing products, which continue to make an important impact on patient's lives. This year, our priority is EXPAREL, which is what I'll focus on today. I'll also touch briefly on PCRX-201....
Read the full article on Seeking Alpha
For further details see:
Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript